{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:23:43Z","timestamp":1781504623921,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.clinthera.2014.02.023","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T07:00:18Z","timestamp":1397631618000},"page":"770-777","source":"Crossref","is-referenced-by-count":37,"title":["Low Vitamin D as a Risk Factor for the Development of Myalgia in Patients Taking High-Dose Simvastatin: A Retrospective Review"],"prefix":"10.1016","volume":"36","author":[{"given":"Kari","family":"Mergenhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-3204","authenticated-orcid":false,"given":"Michael","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kellick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.02.023_bib1","unstructured":"The Use of Medicines in the United States: Review of 2010. http:\/\/www.imshealth.com\/imshealth\/Global\/Content\/IMSInstitute\/Documents\/IHII_UseOfMed_report .pdf. 2011; http:\/\/www.imshealth.com\/imshealth\/Global\/Content\/IMS\/Institute\/Documents\/IHII_UseOfMed_report .pdf. Accessed August 1, 2011."},{"key":"10.1016\/j.clinthera.2014.02.023_bib2","unstructured":"FDA: Limit Use of 80 mg Simvastatin. United States Food and Drug Administration. Consumer Updates. 2011. http:\/\/www.fda.gov\/forconsumers\/consumerupdates\/ucm257884.htm. Accessed June 8, 2011."},{"key":"10.1016\/j.clinthera.2014.02.023_bib3","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.02.023_bib4","unstructured":"Simvastatin. Hudson, OH: Lexi-Comp Inc; 2012."},{"key":"10.1016\/j.clinthera.2014.02.023_bib5","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2014.02.023_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/1402505","article-title":"Selection of variables in multiple regression, part I: a review and evaluation","volume":"46","author":"Thompson","year":"1978","journal-title":"Int Stat Rev"},{"key":"10.1016\/j.clinthera.2014.02.023_bib7","doi-asserted-by":"crossref","first-page":"e28124","DOI":"10.1371\/journal.pone.0028124","article-title":"Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system","volume":"6","author":"Sakaeda","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2014.02.023_bib8","unstructured":"FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm256581.htm. Accessed January 26, 2014."},{"key":"10.1016\/j.clinthera.2014.02.023_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","article-title":"Statin myopathy: incidence, risk factors, and pathophysiology","volume":"9","author":"Sewright","year":"2007","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2014.02.023_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2014.02.023_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.mehy.2011.07.007","article-title":"Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle","volume":"77","author":"Glueck","year":"2011","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.clinthera.2014.02.023_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32 ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.clinthera.2014.02.023_bib13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2008.08.050","article-title":"Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?","volume":"52","author":"Lee","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2014.02.023_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1185\/03007995.2012.702102","article-title":"Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D","volume":"28","author":"Riphagen","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.02.023_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clinthera.2014.02.023_bib16","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T18:23:59Z","timestamp":1538677439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0149291814001404"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}